|
Notification regarding unquoted securities - BDX
|
30 June 2023 at 9:05am
|
|
Proposed issue of securities - BDX
|
30 June 2023 at 8:55am
|
|
BCAL Findings Presented at ASCO Annual Meeting
|
6 June 2023 at 12:40pm
|
|
BCAL Appoints David Darling as Advisor
|
16 May 2023 at 8:45am
|
|
Notification regarding unquoted securities - BDX
|
11 May 2023 at 9:10am
|
|
Change of Director's Interest Notice
|
3 May 2023 at 7:15pm
|
|
BCAL Opens Development & Clinical Service Laboratory
|
3 May 2023 at 1:00pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
24 April 2023 at 11:40am
|
|
Half Yearly Report and Accounts
|
23 February 2023 at 6:00pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
16 January 2023 at 9:30am
|
|
Results of Meeting
|
1 December 2022 at 8:05pm
|
|
Results of Meeting
|
29 November 2022 at 5:45pm
|
|
BCAL AGM Presentation
|
29 November 2022 at 3:20pm
|
|
Shareholder Newsletter
|
16 November 2022 at 9:15am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 October 2022 at 8:40am
|
|
Letter to Shareholders on Annual General Meeting Notice
|
28 October 2022 at 8:25pm
|
|
Notice of Annual General Meeting/Proxy Form
|
28 October 2022 at 8:25pm
|
|
Establishment of Development & Clinical Service Laboratory
|
25 October 2022 at 9:20am
|
|
Appendix 4G and Corporate Governance Statement
|
29 September 2022 at 3:25pm
|
|
Annual Report to shareholders
|
29 September 2022 at 12:05pm
|
|
Preliminary Final Report
|
30 August 2022 at 10:15am
|
|
Application for quotation of securities - BDX
|
29 August 2022 at 8:15am
|
|
Proposed issue of securities - BDX
|
25 August 2022 at 4:45pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 July 2022 at 8:55am
|
|
Change of Director's Interest Notice
|
4 July 2022 at 5:30pm
|
|
BCAL Enters US Product Development Agreement with Precion
|
28 June 2022 at 11:35am
|
|
Change in substantial holding
|
27 June 2022 at 3:10pm
|
|
BCAL Presentation Accepted for 2022 ASCO Annual Meeting
|
1 June 2022 at 8:50am
|
|
Application for quotation of securities - BDX
|
3 May 2022 at 8:35am
|
|
BCAL to Present at NWR Virtual Investor Conference
|
2 May 2022 at 8:50am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2022 at 8:45am
|
|
Shareholder Newsletter
|
24 March 2022 at 11:45am
|
|
Change of Director's Interest Notice
|
2 March 2022 at 6:59pm
|
|
Appendix 4D & Interim Report
|
18 February 2022 at 8:40am
|
|
Shares to be released from escrow
|
14 February 2022 at 10:05am
|
|
7 February Announcement - Additional Information
|
8 February 2022 at 3:10pm
|
|
Recent Analysis Significantly Improves Commercial Prospects
|
7 February 2022 at 9:00am
|
|
Appendix 4C Revised
|
4 February 2022 at 4:25pm
|
|
Becoming a substantial holder
|
31 January 2022 at 5:10pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
27 January 2022 at 8:50am
|
|
Dr John Hurrell Appointed Chief Executive Officer
|
11 January 2022 at 8:45am
|
|
Application for quotation of securities - BDX
|
29 December 2021 at 3:30pm
|
|
Change In Directors Interest Notice - Correction
|
13 December 2021 at 6:40pm
|
|
Directors Change of Interest Notice X 2
|
13 December 2021 at 9:25am
|
|
Results of Meeting
|
23 November 2021 at 7:50pm
|
|
Results of Meeting
|
22 November 2021 at 6:05pm
|
|
AGM Presentation
|
22 November 2021 at 4:20pm
|
|
Addendum to Appendix 4C
|
8 November 2021 at 10:10am
|
|
Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test
|
3 November 2021 at 8:45am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 October 2021 at 9:40am
|
